Immuno-Oncology 2016: Programme
View the programme for Immuno-Oncology 2016 online
- Cancer antigens
- Immuno-oncology meets molecular oncology
- Beyond PD-1/PD-L1 axis blockade: Combinations or new molecules
- Biological therapy: Infectious agents at the service of immunotherapy
- Molecular controls of the immune system
- Adoptive T cell therapy
- Antibody based immunotherapy: Checkpoint blockade and biospecifics
- Biomarkers response
- Technological developments
- Immuno-oncology clinical studies across tumour types (melanoma, lung, bladder, breast, GI, CNS, ovarian,…)
ESMO-MORA:The Symposium programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. Learn more about ESMO-MORA recertification.
CME:The programme will also be submitted for accreditation to the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found online here.
The Symposium webcasts will include all the session of the official programme, where speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.